LA JOLLA, Calif., May 5 /PRNewswire/ -- SIBIA Neurosciences, Inc.,
(Nasdaq: SIBI) today announced that Carla M. Suto, Ph.D. has been named Vice
President, HTS and Technology Development.
    Dr. Suto joined SIBIA as Director of HTS in 1996.  Prior to joining SIBIA,
Dr. Suto held the position of Group Leader in the Department of Pharmacology
and Drug Discovery at Signal Pharmaceuticals, Inc.  Previous to Signal, Dr.
Suto was a Senior Research Scientist in the Department of New Leads Discovery
at Ligand Pharmaceuticals, Inc.  From 1987 to 1993, she held positions at
Parke-Davis Pharmaceutical Research Division of the Warner-Lambert Company in
Ann Arbor, Michigan.  Dr. Suto received her B.S. in Biology from Simmons
College in 1981 and a Ph.D. in Biology in 1985 from Brown University.  Dr.
Suto did her post-doctoral training at the M. D. Anderson Hospital and Tumor
Institute in Houston, Texas.
    "The creation of this position reflects SIBIA's commitment to pursuing
ongoing development of technology, ranging from enabling techniques and
instrumentation to the identification and acquisition of drug discovery
targets," said Jeffrey F. McKelvy, Ph.D., SIBIA's Executive Vice President and
Chief Scientific Officer.
    SIBIA Neurosciences, Inc. is engaged in the discovery and development of
novel small molecule therapeutics for the treatment of neurodegenerative,
neuropsychiatric and neurological disorders, many of which have large patient
populations and represent critical unmet medical needs.  SIBIA is a leader in
the development of proprietary drug discovery platforms that combine key tools
necessary for modern drug discovery, including genomics, high throughput
screening, advanced combinatorial chemistry techniques and pharmacology.  The
Company's proprietary molecular targets and drug candidates, together with its
drug discovery technologies and research expertise, have enabled the Company
to establish several corporate collaborations, which currently include
Bristol-Myers Squibb Company and Meiji Seika Kaisha, Ltd., and multiple
technology licensing arrangements.

    This press release contains forward-looking statements that involve risks
and uncertainties.  As a result, actual results could differ materially from
those discussed herein.  These risks and uncertainties include SIBIA's
reliance on corporate partnerships and ability to enter into new corporate
partnerships, whether SIBIA will be successful in demonstrating the safety and
efficacy of SIB-1508Y and SIB-1553A in humans, whether SIBIA will be able to
meet its development goals with respect to its drug candidates and proprietary
targets, SIBIA's early stage of development, the new and uncertain state of
SIBIA's technologies, SIBIA's future capital needs and the uncertainty of
receiving additional funding, uncertainties regarding patents, proprietary
rights and regulatory matters, and other research, development and market
risks.  These and other risks and uncertainties are more fully set forth in
SIBIA's most recently filed Forms 10-Q and 10-K.

Link to this page: